MPC-7869 (R-flurbiprofen), a Selective Aβ42-Lowering Agent, in Alzheimer’s Disease: Results of a 12-Month Phase 2 Trial and 1-year Follow-on Study

Sandra E. Black1, Gordon K. Wilcock2, Judith Haworth1, Suzanne B. Hendrix1, Kenton H. Zavitzk1, Daniel Christmann1, Mary-Helen Binger1, Sharon Bass1, Mark Laughlin1, Edward Swabb2,

1Sunnybrook & Women’s, University of Toronto, Canada; 2University of Bristol, UK; 3Myriad Pharmaceuticals, Inc.; Salt Lake City, Utah; 4University Neuropsychiatric Institute, University of Utah.

MPC-7869 Clinical Rationale

- Novel anti-amyloid treatment strategy for AD
- Selective Aβ42-Lowering Agent (SALA) in vitro & in vivo
- Selective inhibition of Aβ42
- Reduces insoluble amyloid in mouse brain
- Improves spatial reference learning and memory performance in mice
- Effective concentrations achievable in humans at doses that have been well tolerated

Methodology

- Multi-center, Randomized, Double-Blind, Placebo-Controlled Study
- Involving Canada and the United Kingdom
- Mild to moderate Alzheimer’s (MMSE 15-26)
- Followed for 12 months
- 248 Subjects in 3 Treatment Groups (113:48:80 mg BID: Placebo)
- 12 months treatment
- Phase 3 study available in Canada

Outcome Measures

- Primary Efficacy (measured throughout)
  - Activities of Daily Living
  - Global Function
  - Cognition
  - Demographics by Treatment Group

Trial Profile

- Demographics by Treatment Group
- Cognition—Mild Subjects
- Safety: Adverse Events That Occurred in >5% of Patients or Pharmacokinetic Parameters
- Exploratory Analyses: Change in ADCS-ADL
- Safety: Patients with Adverse Events by Treatment Group
- Safety Summary
- Conclusions

Prospective Statistical Analysis Plan

Activities of Daily Living—Mild Subjects

Cognition—Mild Subjects (Mild to moderate AD, MMSE 15-26)

Global Function—Mild Subjects

Exploratory: Drug Concentration Effect

Safety: Discontinuations Over Time

Optional 12 Month Follow-on Study

- Measured Cognition
- Measured Global Function
- Measured Activities of Daily Living
- Measured Safety: Adverse Events

- Change in MMSE at Baseline
- Change in ADCS-ADL
- Change in CDR-SB
- Change in Global Function
- Change in Activities of Daily Living
- Change in Safety: Adverse Events

- Positive effects increasing over time on all scales
- Confirmatory Phase 3 Study Ongoing in US
- Projected Date of Approval
- Projected Date of Launch

Overall, MPC-7869 appeared very well tolerated between 800 mg BID and placebo.